EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Cannovum Cannabis AG (27N0) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Cannovum Cannabis AG €0.22, price €0.58, upside -61.6%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · DE

CC Thin data Sep 23, 2026

Cannovum Cannabis AG

27N0 · XETRA

Weakest SetupStrongly overvalued and low quality.

!Fair value €0.2210 · Strongly overvalued (−62%)
!Quality 47/100
!Weak Growth (revenue 3y −10.8 %/yr)
!Trails peers (0/5)
!Narrow moat 30/100
!Evidence only low, so the estimate is less certain
Watch Cannovum Cannabis AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€26.95 €0.1790 Fair Value €0.2210 Dec 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

45‑month range €0.1790 – €26.95 · fair‑value band €0.1445 – €0.2805 · the €0.5760 price screens above the €0.2210 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Cannovum Cannabis in your weekly email

Every Wednesday you see whether Cannovum Cannabis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cannovum Cannabis AG engages in the manufacturing, wholesaling, and importing of medical cannabis products in Berlin. It also focuses on the import of medical cannabis and medical-scientific education, as well as distribution for facilitated access to cannabis-based therapies.

Show more

Cannovum Cannabis AG engages in the manufacturing, wholesaling, and importing of medical cannabis products in Berlin. It also focuses on the import of medical cannabis and medical-scientific education, as well as distribution for facilitated access to cannabis-based therapies. The company was formerly known as Cannovum AG and changed its name to Cannovum Cannabis AG in April 2023. Cannovum Cannabis AG was incorporated in 2018 and is based in Berlin, Germany.

Stock analysis

Cannovum Cannabis AG (27N0) currently trades at €0.5760, while our model-based Fair Value estimate is €0.2210, implying the stock looks roughly 160.6% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the evidence level at low.

Scenario range: €0.1445 (bear) to €0.2805 (bull), the price of €0.5760 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Cannovum Cannabis AG reported revenue of €0 in FY2024 versus €5.6K in FY2020. Reported net income was −€401K in FY2024.

Key figures

Market cap €1.5M · EPS (TTM) €−0.2200 · Return on equity −537% · Return on assets (EBIT) −226% · Operating margin −77,789% · Revenue (TTM) €4.0K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 22% below its 52-week high and 71% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −62%, 27N0 screens richer than that median.

Fair Value models

Bear €0.1445 Fair Value €0.2210 Bull €0.2805
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) €0.1300 €0.1800 €0.2700 51
All 1 models by family
Asset-Based
NCAV (Graham) €0.1300 €0.1800 €0.2700 51

Open the full fair value analysis →

Notify me when 27N0 reaches fair value

Put 27N0 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 47/100

Of which business quality 48 · Market factors (momentum, volatility) 59

Profitability 0
Margins and returns on capital today
Quality Growth 48
Are margins and returns improving?
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 90
Price trend over the last 3–12 months (market factor)
52W Momentum 73
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

27N0 screens 161% overvalued. Compare with Merck KGaA →

Compare Cannovum Cannabis AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 48 · Below median
Fair Value upside −62% · Bottom 25%
Profitability
Return on assets −146% · Bottom 25%
Growth and dividend
Revenue growth 0% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 2.67× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.15 €108.70 −18%
Takeda Pharmaceutical Company TAK $18.95 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.52 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $72.86 $108.48 +49%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cannovum Cannabis AG · Fair Value
€0.2210 −161%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Cannovum Cannabis AG Fair Value". https://www.fairvalue-calculator.com/stock/27N0

Frequently asked questions

Is Cannovum Cannabis AG (27N0) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €0.2210 versus a price of €0.5760, about −62% upside (overvalued).
What is the fair value of 27N0?
Our model-based fair value for Cannovum Cannabis AG is €0.2210 (as of Sep 23, 2026), built from audited fundamentals. The current price: €0.5760.
What is the quality score of 27N0?
Cannovum Cannabis AG has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cannovum Cannabis AG (27N0)?
Our model-based price target is the fair value of €0.2210 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario €0.1445, optimistic scenario €0.2805. It is a calculation from audited fundamentals, not an analyst target.
What is the Cannovum Cannabis AG stock forecast for 2026?
Our models put fair value at €0.2210, about −62% upside versus a price of €0.5760 (overvalued). Cautious scenario €0.1445, optimistic scenario €0.2805. The calculation is refreshed regularly with new filings.
What is the revenue of Cannovum Cannabis AG (27N0)?
Cannovum Cannabis AG reported trailing-twelve-month revenue of about €4.0K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Cannovum Cannabis AG (27N0)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cannovum Cannabis AG it is €0.2210 per share (as of Sep 23, 2026), against a price of €0.5760. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Cannovum Cannabis AG stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 27N0 trades above its calculated fair value: price €0.5760, fair value €0.2210, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 27N0?
No. The price is what the market pays today (€0.5760); the fair value is what the company's own numbers justify (€0.2210). For Cannovum Cannabis AG the two are €0.3550 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cannovum Cannabis AG worth?
The market values Cannovum Cannabis AG at about €1.5M (market capitalisation, as of Sep 23, 2026). Per share that is €0.5760; our models calculate a fair value of €0.2210 per share.
What do the bullish and bearish scenarios say about 27N0?
Our models span a range for Cannovum Cannabis AG: cautious scenario €0.1445, base €0.2210, optimistic €0.2805 per share (as of Sep 23, 2026, price €0.5760). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 27N0 from its 52-week high?
Cannovum Cannabis AG trades at €0.5760, about 22% below its 52-week high of €0.7360 and 71% above the low of €0.3360 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €0.2210 is for.
Which stocks are comparable to Cannovum Cannabis AG?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cannovum Cannabis AG stock attractive at the current price?
The data as of Sep 23, 2026: price €0.5760, calculated fair value €0.2210 (−62%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 27N0 calculated?
We run Cannovum Cannabis AG through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.2210, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Cannovum Cannabis AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cannovum Cannabis AG (27N0)?
The closing price on Sep 24, 2026 was €0.5760. Our model-based fair value is €0.2210, about −62% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cannovum Cannabis AG right now?
The price sits above even our optimistic bull case (€0.2805). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€0.1445 to €0.2805) leaves room in how you read the outcome.

Key figures of Cannovum Cannabis AG

How large is the market capitalisation of Cannovum Cannabis AG (27N0)?
The market capitalisation of Cannovum Cannabis AG is €1.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Cannovum Cannabis AG (27N0)?
Earnings per share at Cannovum Cannabis AG are €−0.2200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cannovum Cannabis AG (27N0)?
The return on equity (ROE) of Cannovum Cannabis AG is −537% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cannovum Cannabis AG (27N0)?
On an EBIT basis the return on assets of Cannovum Cannabis AG is −226% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cannovum Cannabis AG (27N0)?
The operating margin of Cannovum Cannabis AG is −77,789% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
Free · no account needed

Watch Cannovum Cannabis AG in the live analysis

One click puts Cannovum Cannabis AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.